May. 14 at 6:37 PM
$ACET (part 2):
Financials
• Net loss decreased from
$28.2M to
$20.2M — an improvement of over 28% year-on-year.
• Total operating expenses dropped from
$29.9M to
$21.6M.
• With
$137.6M in cash and investments, the company is funded well into the second half of 2027.
In short: lower costs, more clinical milestones on the horizon, and sufficient runway to reach the most important data readouts.
Nice
